T. Rowe Price Associates
ALT icon

T. Rowe Price Associates’s Altimmune ALT Stock Holding History

T. Rowe Price Associates’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Buy
165,390
+72,878
+79% +$218K ﹤0.01% 2628
2026
Q1 		$285K Buy
92,512
+42,633
+85% +$181K ﹤0.01% 2702
2025
Q4 		$181K Buy
49,879
+8,386
+20% +$36.6K ﹤0.01% 2838
2025
Q3 		$157K Buy
41,493
+7,262
+21% +$28K ﹤0.01% 2837
2025
Q2 		$133K Buy
34,231
+2,753
+9% +$14.9K ﹤0.01% 2832
2025
Q1 		$158K Buy
31,478
+3,332
+12% +$21.1K ﹤0.01% 2716
2024
Q4 		$203K Buy
28,146
+4,158
+17% +$31.8K ﹤0.01% 2675
2024
Q3 		$148K Buy
23,988
+1,320
+6% +$8.94K ﹤0.01% 2750
2024
Q2 		$151K Buy
22,668
+7,430
+49% +$54.8K ﹤0.01% 2663
2024
Q1 		$156K Buy
15,238
+1,821
+14% +$18.5K ﹤0.01% 2688
2023
Q4 		$151K Buy
13,417
+3,370
+34% +$14.1K ﹤0.01% 2626
2023
Q3 		$27K Sell
10,047
-15,600
-61% -$44.8K ﹤0.01% 2837
2023
Q2 		$91K Buy
25,647
+5,847
+30% +$26.3K ﹤0.01% 2715
2023
Q1 		$84K Sell
19,800
-16,100
-45% -$191K ﹤0.01% 2714
2022
Q4 		$591K Sell
35,900
-98,714
-73% -$1.11M ﹤0.01% 2055
2022
Q3 		$1.72M Buy
134,614
+99,014
+278% +$1.46M ﹤0.01% 1516
2022
Q2 		$417K Sell
35,600
-3,453
-9% -$21.3K ﹤0.01% 2293
2022
Q1 		$238K Buy
39,053
+834
+2% +$6.14K ﹤0.01% 2648
2021
Q4 		$350K Buy
38,219
+5,900
+18% +$62.7K ﹤0.01% 2539
2021
Q3 		$366K Buy
32,319
+334
+1% +$4.06K ﹤0.01% 2508
2021
Q2 		$315K Sell
31,985
-16,115
-34% -$220K ﹤0.01% 2580
2021
Q1 		$680K Buy
48,100
+7,100
+17% +$115K ﹤0.01% 2223
2020
Q4 		$462K Buy
41,000
+24,600
+150% +$290K ﹤0.01% 2274
2020
Q3 		$216K Buy
+16,400
New +$328K ﹤0.01% 2401
2013
Q3 		– Sell
-1,267
Closed -$604K – 2456
2013
Q2 		$604K Buy
+1,267
New +$628K ﹤0.01% 1800

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's ALT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Altimmune (ALT) stake by 79% in Q2 2026, buying an estimated $218K and bringing the position to 165,390 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

T. Rowe Price Associates first reported a position in ALT in Q2 2013 and has held it in 25 quarters since. The position peaked at $1.72M in Q3 2022. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • T. Rowe Price Associates held 165,390 shares of Altimmune worth $503K as of Q2 2026.
  • T. Rowe Price Associates bought 72,878 Altimmune shares in Q2 2026, an estimated $218K.
  • Altimmune made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2628 holding.
  • T. Rowe Price Associates first reported a position in Altimmune in Q2 2013 and has held it in 25 quarters since.
  • T. Rowe Price Associates's Altimmune position peaked at $1.72M in Q3 2022.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.